Bethesda, MD – According to filings with the U.S. Securities and Exchange Commission, Precision Medicine Group is raising $35,160,000.00 in new funding. Sources indicate as part of senior management Co-Founder, Mark Clein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Precision Medicine Group

As a global research, development, manufacturing, and commercialization partner, we leverage the discipline of precision medicine as our foundation, arming our experts with data and technology that enable us to solve complex challenges. We are purpose-built to accelerate complicated clinical development by efficiently executing complex studies and maximizing insight into patient biology. We integrate deep science, advanced technology, clinical trial expertise, and manufacturing services to advance clinical development around the globe reducing costs, minimizing risks, and accelerating access  to life-changing treatments. Across the commercialization continuum, our team transforms and leverages evidence and insights to tailor communications for every stakeholder. From payers to health systems, scientists to healthcare providers, consumers to advocates, our results are designed to shift the trajectory and accelerate success.

To learn more about Precision Medicine Group, visit http://www.precisionmedicinegrp.com/

Contact:
Mark Clein, Co-Founder
240-654-0730
mark.clein@precisionmedicinegrp.com
https://www.linkedin.com/in/mark-clein-22a63a11/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved